Featured Publications
Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies
De Aquino JP, Parida S, Avila-Quintero VJ, Flores J, Compton P, Hickey T, Gómez O, Sofuoglu M. Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies. Drug And Alcohol Dependence 2021, 228: 109097. PMID: 34601272, PMCID: PMC8595687, DOI: 10.1016/j.drugalcdep.2021.109097.Peer-Reviewed Original ResearchMeSH KeywordsAcute PainAnalgesiaAnalgesics, OpioidBuprenorphineFemaleHumansMaleMethadoneOpiate Substitution TreatmentOpioid-Related DisordersConceptsOpioid agonist therapyOpioid use disorderExperimental pain studiesAbuse potentialRespiratory depressionAcute painPain studiesUse disordersSystematic reviewGreater abuse potentialHigh-potency opioidsMethadone-maintained personsSignificant pain reliefRespiratory depressant effectsHigh-potency compoundsOpioid naïveAgonist therapyOpioid dosesPain reliefAnalgesic effectSevere painDepressant effectAdditional dosesStudy qualityHealthy personsThe impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies
Costa G, Nunes J, Heringer D, Anand A, De Aquino J. The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies. The American Journal Of Drug And Alcohol Abuse 2024, 50: 12-26. PMID: 38225727, DOI: 10.1080/00952990.2023.2287406.Peer-Reviewed Original ResearchConceptsNon-medical opioid useOpioid use disorderOpioid useCannabis useOpioid use disorder pharmacotherapyUse disorderImpact of cannabis useAverage follow-up timeFollow-up timeMeta-analysisEvidence of moderate heterogeneityImpact of cannabisPooled odds ratioOpioids non-medicallyRandom-effects modelMeta-analysis of longitudinal studiesCannabis abstinenceTreatment modalitiesOdds ratioModerate heterogeneityPharmacotherapyCannabisOpioidComprehensive searchPublication bias
2023
Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study
De Aquino J, Meyerovich J, Xie C, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M. Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study. Addiction Biology 2023, 28: e13317. PMID: 37644897, PMCID: PMC10468603, DOI: 10.1111/adb.13317.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyAgonist therapyMethadone dosesMethadone therapyPain sensitivityUse disordersPlacebo-controlled laboratory studySynergistic antinociceptive effectCognitive adverse effectsSingle oral dosesRisk-benefit profilePain sensitivity measuresCannabinoid receptor systemAntinociceptive effectTHC doseOral dosesOpioid agonistsAcute effectsCannabinoid agonistsPreclinical studiesAbuse potentialOpioid crisisTherapyReceptor system
2022
Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies
De Aquino J, Bahji A, Gómez O, Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug And Alcohol Dependence 2022, 241: 109702. PMID: 36434879, PMCID: PMC9772106, DOI: 10.1016/j.drugalcdep.2022.109702.Peer-Reviewed Original ResearchConceptsOpioid withdrawalObservational studySystematic reviewDelta-9-tetrahydrocannabinol administrationPlacebo-controlled clinical trialCannabis useNon-opioid therapeuticsPotential of cannabinoidsDose of opioidsOpioid withdrawal symptomsOpioid use disorderNarrow therapeutic windowExperimental human studiesDose-dependent increaseMain psychoactive constituentPatient characteristicsWithdrawal symptomsClinical trialsPharmacological factorsStudy qualityTherapeutic windowTherapeutic benefitUse disordersHuman studiesAbuse liability
2021
The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
De Aquino JP, Parida S, Sofuoglu M. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. Clinical Drug Investigation 2021, 41: 425-436. PMID: 33818748, PMCID: PMC8020374, DOI: 10.1007/s40261-021-01032-7.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineHumansNarcotic AntagonistsOpioid-Related DisordersReceptors, Opioid, muSubstance Withdrawal SyndromeConceptsUnique pharmacological profileOpioid use disorderOpioid withdrawalPotential dose-dependent effectsPlacebo-controlled clinical trialLong-term treatment outcomesFull opioid agonistsStandard induction regimensOpen-label studyFirst-line pharmacotherapySchedule of administrationMu-opioid receptorsAvailability of buprenorphineDose-dependent effectFuture translational researchInduction regimensOpioid taperOpioid toneFirst doseClinical outcomesClinical evidenceOpioid agonistsBuprenorphine formulationsDaily dosesClinical trials
2020
Impact of cannabis on non-medical opioid use and symptoms of posttraumatic stress disorder: a nationwide longitudinal VA study
De Aquino JP, Sofuoglu M, Stefanovics EA, Rosenheck RA. Impact of cannabis on non-medical opioid use and symptoms of posttraumatic stress disorder: a nationwide longitudinal VA study. The American Journal Of Drug And Alcohol Abuse 2020, 46: 812-822. PMID: 33035104, DOI: 10.1080/00952990.2020.1818248.Peer-Reviewed Original ResearchConceptsNon-medical opioid usePosttraumatic stress disorderOpioid useNon-medical opioidsPTSD symptomsCannabis useStress disorderSubstance useBaseline cannabis useImpact of cannabisSevere PTSD symptomsIntensive PTSD treatmentMore PTSD symptomsPTSD treatmentU.S. veteransSymptomsVA studyCannabisVeteransOpioidsSubstitution agentsBaselineDaysDisordersTreatment
2019
High potency synthetic opioids: Curbing the third wave of the opioid crisis
Parida S, De Aquino JP, Sofuoglu M. High potency synthetic opioids: Curbing the third wave of the opioid crisis. Neuroscience & Biobehavioral Reviews 2019, 106: 9-10. PMID: 31251966, DOI: 10.1016/j.neubiorev.2019.06.019.Peer-Reviewed Original ResearchAdverse Consequences of Co-Occurring Opioid Use Disorder and Cannabis Use Disorder Compared to Opioid Use Disorder Only
De Aquino JP, Sofuoglu M, Stefanovics E, Rosenheck R. Adverse Consequences of Co-Occurring Opioid Use Disorder and Cannabis Use Disorder Compared to Opioid Use Disorder Only. The American Journal Of Drug And Alcohol Abuse 2019, 45: 527-537. PMID: 31112429, DOI: 10.1080/00952990.2019.1607363.Peer-Reviewed Original ResearchConceptsDrug use disordersOpioid use disorderUse disordersOpioid prescriptionsCo-occurring opioid use disordersNational Veterans Health Administration dataVeterans Health Administration dataCo-occurring opioidEmergency department visitsHealth Administration dataInpatient psychiatric admissionCannabis use disorderOpioid prescribingClinical characteristicsED visitsDepartment visitsInpatient admissionsPsychiatric admissionsFiscal year 2012Lower riskPatientsBivariate analysisAdministration dataDisordersHigher likelihood